Navigation Links
Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
Date:10/27/2008

POT-4 is the first complement inhibitor to be tested in AMD patients

LOUISVILLE, Ky., Oct. 27 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that the Company will be presenting its ASaP Phase I clinical data for its leading drug candidate, POT-4, during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) Annual Meeting in Atlanta, GA, on November 7, 2008.

Cedric Francois, President and CEO of Potentia Pharmaceuticals, said, "POT-4 is the first of several complement inhibitors that will ultimately be tested in macular degeneration. The role of complement in this disease was established in 2005 as the first breakthrough discovery resulting directly from the human genome project. If complement inhibition is successful at treating macular degeneration, it would be the first of hopefully many new drugs born out of the human genome project, and usher in an era of improved healthcare for millions of patients."

Dr. Philip J. Rosenfeld, M.D., Ph.D., Professor of Ophthalmology at the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine in Miami, FL, and a clinical investigator in the study, will present the data on Potentia's behalf.

POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factor (VEGF) in the eye. Based on this mechanism of action, POT-4 holds the potential to be effective against both dry and wet AMD. POT-4 has shown early positive safety results in its Phase I study.

For more information on the presentation at AAO:

Title: Complement C3 Inhibitor POT-4 for AMD

When: Friday, November 7 at 9:01 AM EST

Location: Hall A-3 Session Room

Se
'/>"/>

SOURCE Potentia Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
3. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
9. Discovery of creator gene for cerebral cortex points to potential stem cell treatments
10. Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs
11. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... 14, 2014 The largest international professional organization ... and therapeutic derivatives thereof has endorsed an educational ... about the challenges of adulterated herb and botanical ... The Society for Medicinal Plant and ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... Calif., May 11 Apex Bioventures Acquisition Corporation (NYSE ... that it has received notice from NYSE Amex LLC ... the Company has been accepted by the Exchange and ... 11, 2009 to regain compliance with the continued listing ...
... deCODE genetics,(Nasdaq: DCGN ) today announced its ... A conference call to discuss these results and,recent developments ... May 12, at 8:00am Eastern Daylight Time/12 noon GMT/1pm ... Net loss for the quarter ended March 31, 2009 ...
... May 11 Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ... overview at the upcoming Deutsche Bank 2009 Health Care Conference ... the Intercontinental Hotel, Boston.The live and archived webcast of the ... the Idenix Investor Center at www.idenix.com . ...
Cached Biology Technology:Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex 2deCODE genetics Announces First Quarter 2009 Financial Results 2deCODE genetics Announces First Quarter 2009 Financial Results 3deCODE genetics Announces First Quarter 2009 Financial Results 4deCODE genetics Announces First Quarter 2009 Financial Results 5deCODE genetics Announces First Quarter 2009 Financial Results 6deCODE genetics Announces First Quarter 2009 Financial Results 7deCODE genetics Announces First Quarter 2009 Financial Results 8
(Date:4/22/2014)... team of Yale researchers will lead a five-year, $3 ... rain events is affecting the transport of dissolved organic ... they say could alter the chemical composition and water ... With funding from the National Science Foundation,s MacroSystems Biology ... across the watershed, which begins in Canada and runs ...
(Date:4/22/2014)... RIVERSIDE, Calif. Inspired by the fist-like club ... by University of California, Riverside, in collaboration with University ... design structure for composite materials that is more impact ... , "The more we study the club of this ... improve so many things we use every day," said ...
(Date:4/22/2014)... American Societies for Experimental Biology (FASEB) has released ... how funding from the National Institutes of Health (NIH) ... Rico. "FASEB is pleased to make these factsheets available ... NIH to their state," said FASEB President, Margaret K. ... for biomedical research funding, investing $29.2 billion in ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3
... role of the Dicer. MicroRNAs are emerging as ... an RNaseIII enzyme, plays a role in the biogenesis ... activity to determine the developmental role of DICER by ... p. 696 of this issue, Maatouk et al. add ...
... new insight into how the cell,s vast array of ... lethally malfunctioning molecules without a system for proteins to ... Just as eyeglasses improve vision, a coat provides warmth ... set of proteins called ubiquitin-like proteins (UBLs) as accessories ...
... after being exposed to a specialized electrical field is ... a stage of cancer already invading other parts of ... process and found cells that expanded the most were ... spread beyond its point of origin. The technique allows ...
Cached Biology News:October 2008 Biology of Reproduction highlights 2St. Jude study gives new insights into how cells accessorize their proteins 2St. Jude study gives new insights into how cells accessorize their proteins 3Expanding cell girth indicates seriousness of breast cancer 2